
- Corporate
Financial Results 9M 2026
In the first nine months of 2026, we continued to deliver solid results, driven by strong commercial and operational execution and the continued growth of our European Dermatology business. Total Net Sales increased by 8.3% year-on-year to €889.2 million, while EBITDA grew by 22.7% to €221.7 million, reaching a 24.9% margin.

















